SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis
A survey-based study analyzed vaccination reactions and disease deterioration after SARS-CoV-2 vaccination among more than 6,000 MS patients in Germany and the United Kingdom.
Read More »
Pfizer
SLE Flares Post COVID-19 Vaccine
A study in Japan analyzed the association between mRNA Covid-19 vaccination and medium-term SLE flare-ups. At 30 days after completion of a primary series, the rate of mild or moderate SLE flares was 20.3% within the vaccinated group, versus 23.3% in the unvaccinated group. Flare rates at 60 and 90 days were similar between both groups.
Read More »COVID-19 Vaccine Responses in those with Renal Autoimmune Diseases
A new study investigated how effective a two-dose SARS-CoV-2 vaccine regimen is for patients receiving Rituximab. Researchers measured the humoral and cellular immune responses, which correlate to antibody and T-cell production, respectively.
Read More »IgG Antibody Responses Across 3 Doses of mRNA Vaccines
A study published in the Journal of Autoimmunity evaluated the immune response of Pfizer and Moderna’s mRNA COVID-19 vaccines in participants with autoimmune systemic diseases. In total, serum samples from 244 AD patients were collected 2-4 weeks and six months after their first vaccine cycle, and 2-4 weeks following their booster dose; 502 people from the general population were used as a control group.
Read More »